Every investor wants to net a 10-bagger, and if you're like most of us, you're impatient to see your money grow. For an investment of $1,000 to reach $10,000 by a relatively close deadline like late 2030, eight years from now, a stock would need to rise by around 33% annually. Most companies can't do that since rapid growth years are often followed by underperforming years.

But when it comes to biotech businesses that don't yet have a medicine approved for sale, massive stock price movements in relatively short periods are not uncommon. This kind of growth is possible in biotech because there are major catalysts like clinical trial results and regulatory decisions that resolve significant uncertainty about a company's prospects of reaching financial success.

One way to find players with the greatest potential is to identify those that are exposed to the most (and highest-impact) catalysts ahead. Let's look at a pair of budding biotech growth stocks that have a solid chance of returning $10,000 from a humble investment of around $1,000.

Continue reading

Source Fool.com